Pulmatrix Raises $1M in Preferred Stock Financing

Pulmatrix ( (PULM) ) just unveiled an announcement.

On April 16, 2026, Pulmatrix closed a $1 million private placement of Series B Convertible Preferred Stock with an affiliate of Eos SENOLYTIX at a conversion price of $2.20 per share, a transaction announced on April 21, 2026 as part of the planned merger between the two companies. The preferred shares, issued under U.S. private offering exemptions and carrying voting rights alongside common stock, are intended to provide working capital and general corporate funding as Pulmatrix advances the merger process and aligns with investors backing Eos.

Spark’s Take on PULM Stock

According to Spark, TipRanks’ AI Analyst, PULM is a Neutral.

The score is held down primarily by very weak fundamentals (near-zero TTM revenue, ongoing losses and cash burn, and a shrinking equity base) and a strong bearish technical trend (price well below key moving averages with negative MACD). Corporate events add some upside via a proposed merger and new financing, but the high dilution and recent deal termination keep overall risk elevated.

To see Spark’s full report on PULM stock, click here.

More about Pulmatrix

Pulmatrix, Inc. is a biopharmaceutical company developing novel inhaled therapeutic products to prevent and treat migraine and serious respiratory diseases using its patented iSPERSE dry powder technology. Its pipeline targets central nervous system disorders such as acute migraine and lung diseases including COPD and allergic bronchopulmonary aspergillosis, aiming to improve lung drug delivery, pharmacokinetics and patient outcomes.

Average Trading Volume: 45,667

Technical Sentiment Signal: Sell

Current Market Cap: $4.57M

For detailed information about PULM stock, go to TipRanks’ Stock Analysis page.